Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook have?
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook has 1,153 citations in the OpenAlex counts ScholarIQ stores.
When was Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook published?
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook has 2020 year in the ScholarIQ index.
What is the open-access status of Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook?
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook has closed oa status in the ScholarIQ index.
What is the DOI of Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook?
The DOI for Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook is on the source record.
What is the PMID of Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook?
The PMID for Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook is on the source record.
What is the OpenAlex record for Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook?
The OpenAlex for Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook is on the source record.